[ad_1]
DUBLIN – (COMMERCIAL THREAD)–The “China Pharmaceutical and Healthcare Industry – Forecast and Analysis 2021” report was added to ResearchAndMarkets.com offer.
The COVID-19 pandemic has had a huge impact on China’s pharmaceutical and healthcare industry, as industry analysts expect a rapid return to normal demand levels.
China’s pharmaceutical and healthcare industry is one of the largest markets in the world, and it is fast becoming a leading global hub for drug innovation and development. Even as the COVID-19 crisis rages on, there is growing international investment in China’s pharmaceutical and healthcare sectors.
China’s healthcare and pharmaceutical landscape sees promising new healthcare reforms in the coming years as the government seeks to deliver quality healthcare to the growing demand of its people. On March 5, 2021, the government announced institutional health care reforms in line with China’s 14th Five-Year Plan (2021-2025).
The government has also highlighted a detailed roadmap to improve the overall quality of health care in the country while developing the necessary services in this sector. With generic drugs being the mainstay of the country’s population, generics made up nearly 65% ​​of the entire pharmaceutical industry in 2020.
While growth in the pharmaceutical industry is unlikely to return to pre-pandemic heights, China will continue to remain one of the largest markets for drug makers in the world.
The report covers the following data:
-
In-depth coverage of the pharmaceutical and healthcare industry in China by sectors along with an analysis of how the COVID-19 pandemic is affecting the industry.
-
We analyze the prescription drug, generic drug, over the counter drug segments and also analyze the medical research and clinical trial landscape in China.
-
A SWOT analysis of the Chinese pharmaceutical and healthcare industry.
-
A strategic analysis of Porter’s five forces on the Chinese pharmaceutical and healthcare industry is included, which examines the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and substitution of industry.
-
We take a close look at the regulatory framework governing the Chinese pharmaceutical and healthcare industry, and the challenges faced in terms of intellectual property rights. An analysis of China’s 14th Five-Year Health Care Reform Plan is also included in this section.
-
Competition in the industry, as well as an in-depth analysis of domestic and multinational industry players such as Shanghai Pharmaceuticals Holding, Sinopharm Group, Tasly Pharmaceutical Group, China Shijiazhuang Pharmaceutical Group, AstraZeneca, Eli Lilly (Lilly China), Novartis, and many more others are included.
Main topics covered:
A. Executive summary
B. Definition of industry
C. Brief overview of the pharmaceutical and healthcare sector APAC
D. Pharmaceutical and healthcare industry in China
D.1 Impact of COVID-19 on industry
D.2 Analysis of the pharmaceutical sector
D.3 Health sector analysis
D.4 Prescription drug market
D.5 Patented medicine market
D.6 Over-the-counter drugs market
D.7 Generic drug market
D.8 Medical research and clinical trials in China
E. Pharmaceutical and healthcare industry in China: SWOT analysis
E.1 Forces on which to build
E.2 Weaknesses to overcome
E.3 Opportunities to be exploited
E.4 Threats to be overcome
F. Chinese Pharmaceutical Industry: Analysis of Porter’s Five Forces Strategy
F.1 Overview
F.2 Bargaining power of buyers
F.3 Bargaining power of suppliers
F.4 Competitive Rivalry in Industry
F.5 Threat of new entrants
F.6 Threat of substitutes
G. Chronic medical conditions in China
G.1 Overview
G.2 Cancer
G.3 Chronic obstructive pulmonary disease
G.4 Diabetes
H. Industry regulatory framework
H.1 Presentation
H.2 China’s 14th Five-Year Health Care Reform Plan
H.3 Regulations governing over-the-counter drugs
H.4 Regulations governing biosimilars
H.5 Challenges with intellectual property rights
H.6 Challenges with counterfeit medicines
H.7 Pricing and reimbursement regime
H.8 Regulations governing the marketing of pharmaceutical products
I. Import / Export of pharmaceutical products in China
J. Competition in industry
J.1 Competitive landscape
J.2 Competition in generic drugs
J.3 Competition in the pharmaceutical sector
J.4 Competition in the distribution of medicines
K. Forecast: Pharmaceutical and healthcare industry in China
K.1 Prospects for the Chinese Pharmaceutical Industry
K.2 Prospects for the Chinese healthcare industry
K.3 Outlook for the prescription drug sector
K.4 Patented Medicines Market Outlook
K.5 OTC Drug Market Outlook
K.6 Generic Drugs Market Outlook
L. Main national and multinational actors
-
China Grand Pharmaceutical and Healthcare Holdings Ltd
-
China Resources Pharmaceutical Group Ltd.
-
Chinese pharmaceutical group Shijiazhuang
-
Harbin Pharmaceutical Group
-
Jiangsu Hengrui Medicine Co. Ltd.
-
Jiangsu Simcere Pharmaceutical Co. Ltd.
-
Luye Pharma Group Ltd.
-
Nanjing Pharmaceutical
-
North China Pharmaceutical Corporation
-
Shanghai Fosun Pharmaceutical (Group) Co Ltd
-
Shanghai Pharmaceuticals Holding Co.
-
Shijiazhuang Yiling Pharmaceutical Co Ltd
-
Sihuan Pharmaceutical Holdings Group Ltd.
-
Sino Biopharmaceutical Limited
-
Sinopharm Group
-
Sundia MediTech Co. Ltd.
-
Tasly Pharmaceutical Group
-
Zhejiang Hisun Pharmaceutical
-
AstraZeneca
-
Bayer Healthcare
-
Eli Lilly and Co. (Lilly China)
-
GlaxoSmithKline
-
Merck & Co.
-
Novartis
-
Pfizer
-
rock
-
Sanofi SA
For more information on this report, visit https://www.researchandmarkets.com/r/cavx5l
[ad_2]
